Pharmaceutical care for a case of Parkinson's syndrome caused by trimetazidine hydrochloride tablets in an elderly patient with renal insufficiency

doi:10.19803/j.1672-8629.20220211

Abstract

Abstract: Objective To investigate the causes and mechanisms of parkinsonism induced by trimetazidine hydrochloride tablets in elderly patients with renal insufficiency, and to provide reference for rational clinical use of trimetazidine hydrochloride tablets. Methods The course of treatment of one patient after taking trimetazidine hydrochloride tablets was analyzed while related literature was reviewed. Results Parkinsonism occurred one day after treatment with trimetazidine hydrochloride tablets, but disappeared when these tablets were discontinued. Conclusion Trimetazidine hydrochloride tablets may increase the risk of parkinsonism in elderly patients with renal insufficiency and should be monitored during clinical use.

Key words: trimetazidine dihydrochloride tablets, parkinsonism, renal insufficiency, elderly patients, adverse drug reaction

CLC Number:

R972
R969.3

ZHANG Yuan, HE Mei. Pharmaceutical care for a case of Parkinson's syndrome caused by trimetazidine hydrochloride tablets in an elderly patient with renal insufficiency[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 343-345.

References

[1] MARZILLI M, VINEAREANU D, LOPASCHUK G, et al.Trimetazidine in cardiovascular medicine[J]. International Journal of Cardiology, 2019, 293: 39-44.
[2] DY AMB, LIMJOCO LLG, JAMORA RDG.Trimetazidine-induced parkinsonism: a systematic review[J]. Frontiers in Neurology, 2020, 11(44): 1-6.
[3] DÁVID P, DÁNIEL B, ANDRÁS Aet al. Trimetazidine use in parkinson’s disease: is it a resolved problem?[J]. eNeuro, 2021, 8(3): 0452-20.2021.
[4] ZHENG FY, WU Y, RAO YF, et al.The role of the Naranjo’s scale in the evaluation of adverse drug reactions and an example analysis[J]. Chinese Journal of Pharmacy(中国药学杂志), 2012, 47(8): 650-652.
[5] BONDON-GUITTON E, PEREZ-LLORET S, BAGHERI H, et al.Drug-induced parkinsonism: a review of 17 years’ experience in a regional pharmacovigilance center in France[J]. Movement Disorders, 2011, 26(12): 2226-2231.
[6] WENNING GK, KIECHL S, SEPPI K, et al.Prevalence of movement disorders in men and women aged 50-89 years (Bruneck Study cohort): a population-based study[J]. The Lancet Neurology, 2005, 4(12): 815-820.
[7] PINTER D, KOVACS M, HARMAT M, et al.Trimetazidine and parkinsonism: a prospective study[J]. Parkinsonism and Related Disorders, 2019, 62(1): 117-121.
[8] THANYI B, TREADWELL S.Drug induced parkinsonism: a common cause of parkinsonism in older people[J]. Postgraduate Medical Journal, 2009, 85(1004): 322-328.
[9] MARTI MASSO JF.Parkinsonismo por trimetazidina[J]. Neurologia, 2004, 19(7): 392-397.
[10] MEI LL, REN F, ZHANG WF, et al.Research progress of Parkinson syndrome associated with trimetazidine[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2020, 22(12): 689-692.
[11] SIVET J, GASTINE B, MOSQUET B, et al.Trimetazidine-induced encephalopathy with choreiform disorders: a case report[J]. La Revue De Médecine Interne, 2008, 29(6): 512-515.
[12] BARRE J, LEDUDAL P, OOSTERHUIS B, et al.Pharmacokinetic profile of a modified release formulation of trimetazidine (TMZ MR 35 mg) in the elderly and patients with renal failure[J]. Biopharmaceutics & Drug Disposition, 2003, 24(4): 159-164.
[13] MASMOUDI K, MASSON H, GRAS V, et al.Extrapyramidal adverse drug reactions associated with trimetazidine: a series of 21 cases[J]. Fundam Clin Pharmacol, 2012, 26(2): 198-203.
[14] FABIANI G, PASTRO PC, FROEHNER C.Parkinsonism and other movement disorders in outpatients in chronic use of cinnarizine and flunarizine[J]. Arquivos de Neuro-Psiquiatria, 2004, 62(3-B): 784-788.
[15] BRUCKE T, WOBER C, PODREKA I, et al.D2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects. aspect study[J]. Journal of Cerebral Blood Flow & Metabolism Official Journal of the International Society of Cerebral Blood Flow & Metabolism, 1995, 15(3): 513-521.
[16] NEGROTTI A, CALZETTI S.A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism[J]. Movement Disorders, 1997, 12(1): 107-117.
[17] TEIEVE HA, TROIANO AR, GERMINIANI FM, et al.Flunarizine and cinnarizine-induced parkinsonism: a historical and clinical analysis[J]. Parkinsonism and Related Disorders, 2004, 10(4): 243-245.
[18] WANG JL, ZHANG XM, ZHANG B, et al.Safety of medications for cardiovascular diseases in community clinics[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2022, 19(7): 744-748.